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Abstract 1 
We have synthesized polylactide (PLA) polymers containing five distinct lengths of 2 
fluorinated end-groups (from C3F7 to C13F27). The influence of fluorinated end-groups length 3 
and their dynamics in chlorinated solvents (chloroform and dichloromethane) was 4 
investigated as a function of the presence of perfluohexane (PFH) and related to the 5 
morphology of capsules of PFH obtained using these fluorinated polylactides. 19F spin-spin 6 
relaxation time (T2) measurements revealed a reduced mobility of the fluorinated units with 7 
dependency on fluorinated chain length in the order C3F7>C8F17>C13F27. The presence of 8 
perfluorohexane (PFH) led to a further decrease on the segmental mobility, indicating the 9 
existence of fluorous interactions. The T2 relaxation time of the CF3 resonance of PLA-C3F7 10 
decreased from 540±50 ms in CDCl3 to 81±15 ms after the addition of PFH. Due to these 11 
fluorous interactions, PLA polymers containing short fluorinated groups (C3F7 and C6F13) led 12 
to microcapsules with core-shell morphologies, whereas those formulated with long F-units 13 
(C8F17, C11F23 and C13F27) favored the formation of multinucleated capsules as observed by 14 
confocal microscopy. 15 
 16 
 17 
 18 
 19 
 20 
 21 
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1. Introduction 22 
Fully and partly fluorinated compounds are widely explored in the chemical industry and 23 
academic research for their inherent immiscibility with hydrophobic and lipophobic solvents. 24 
This so-called “fluorophilic” character is responsible for low or “gas like” intermolecular 25 
attractions which confer to such molecules inertness and biocompatibility, features that 26 
attracted special attention for a wide range of biomedical applications1,2. In particular, liquid 27 
perfluorocarbons (PFCs), such as perfluorohexane (PFH) or perfluorooctyl bromide (PFOB) 28 
are described to be minimally absorbed, eliminated from the lungs by evaporation and did 29 
not lead to any significant histological, cellular or biochemical disturbance 3. Therefore, these 30 
PFCs are intensively investigated for their potential to act as intravascular contrast agents 4.  31 
Recent reports describe the use of capsules containing PFOB to provide in vivo 19F-MRI or 32 
ultrasound detection and also passively deliver chemotherapeutics to cancer cells 5–9. Similar 33 
formulations use PFH as an active core for its lower boiling point, as it favors liquid-to-gas 34 
transition by acoustic and thermal stimuli, allowing real-time ultrasonic imaging as well as 35 
localized drug-release 10–12. Nonetheless, the entrapment of fully fluorinated PFCs, such as 36 
PFH, within a polymeric shell is proving to be difficult due to their dual lipophobic and 37 
hydrophobic character and their trend to easily evaporate during formulation 14. Several 38 
groups have turned to the use of fluorinated surfactants or lipids to improve PFCs 39 
encapsulation 15–17. Literature also reports the functionalization of polymer with fluorinated 40 
end-groups to favor interactions with PFCs 11,14,18–24. It was previously demonstrated that a 41 
wide range of fluorinated end-groups linked to the PLA chain – from C3F7 to C13F27 – 42 
increased the entrapment of PFCs into nanocapsules, resulting in more efficient acoustic 43 
responses14,19. However, no significant distinction regarding the morphology or PFC 44 
entrapment was observed by increasing the length of the end-fluorinated groups in 45 
nanoformulations.  46 
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The main objective of this study is to investigate deeper the influence and extent of fluorous 47 
interactions between fluorinated end-groups of PLA-CxF2x+1 and PFH on the final morphology 48 
of microcapsules (MC) as a function of fluorinated end-group length. In particular, we 49 
examine the role of the solvent in which the polymer was dissolved on the strength of 50 
fluorous interactions by comparing chloroform and dichloromethane, two solvents often used 51 
to formulate polymer particles and capsules 25,26. To fully explore the impact of fluorinated 52 
end-group chain length and solvent, end-group dynamics and PFH entrapment efficiency 53 
were evaluated by NMR and MC morphology was assessed by confocal microscopy. This 54 
study provides information for the morphological design of new ultrasound activable systems 55 
formulated with fluorinated PLA polymers. 56 
 57 
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2. Materials and Methods 58 
2.1 Materials 59 
D,L-lactide was purchased from Polysciences (Germany) and perfluorohexane 98+% was 60 
acquired from Alfa Aesar (Germany). 1-hexanol was obtained from Acros Organics 61 
(Belgium), 2,2,3,3,4,4-heptafluoro-1-butanol, 1H,1H perfluoro-1-heptanol, 1H,1H perfluoro-1-62 
nonanol, 1H,1H perfluoro-1-dodecanol and 1H,1H perfluoro-1-tetradecanol were acquired 63 
from Fluorochem (United Kingdom). Acetone, tetrahydrofuran (THF) and dichloromethane 64 
were purchased from Carlo Erba Reactifs (France), chloroform and diethyl ether from VWR 65 
(France). Nile red, stannous octoate, sodium cholate, trifluoroacetic acid (TFA), deuterated 66 
chloroform and deuterated dichloromethane were provided by Sigma-Aldrich (France). The 67 
ultrapure water was produced by a RIOS/Milli-Q system (Millipore, France), with a resistivity 68 
of 18.2 MΩcm. The NMR sample tubes and coaxial inserts were obtained from CortecNet 69 
(France). 70 
2.2 Polymer Synthesis 71 
All fluorinated (PLA-C3F7, PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27) and non-72 
fluorinated (PLA-C6H13) derivatives of polylactide polymers were synthesized by ring opening 73 
polymerization (ROP) with the presence of stannous octoate as catalyst 27,28. All glassware 74 
and stir bars were flame-dried and cooled under argon flow. Briefly, in a 10 mL schlenck tube 75 
equipped with a magnetic stir-bar, the D,L-lactide (10.4 mmol, 1.5 g) and corresponding 76 
initiator (0.075 mmol) – 1-hexanol for PLA-C6H13, 2,2,3,3,4,4-heptafluoro-1-butanol for PLA-77 
C3F7, 1H,1H perfluoro-1-heptanol for PLA-C6F13, 1H,1H perfluoro-1-nonanol for PLA-C8F17, 78 
1H,1H perfluoro-1-dodecanol for PLA-C11F23 or 1H,1H perfluoro-1-tetradecanol for PLA-79 
C13F27 – were added to the flask under argon flow. The tube was sealed with a rubber cap 80 
and a stannous octoate solution (0.05 mmol, 20 mg) dissolved in 2 mL of dried toluene was 81 
added through the septum. The tube was purged with argon for 0.5 h and the polymerization 82 
reaction was conducted with continuous stirring at 130 °C for 55 minutes in an oil bath under 83 
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argon flow. The reaction was quenched by immersing the flask in a cold water bath. 84 
Afterwards, the solvent was evaporated under reduced pressure for 1h and the material was 85 
dissolved in 5 mL of chloroform. The product was purified by precipitation as previously 86 
described29: all polymers were precipitated into cold diethyl ether (80 mL), next, PLA-C6H13 87 
was dissolved into THF (5 mL), whereas the fluorinated polymers were dissolved in acetone 88 
(20 mL) and precipitated again in ultrapure water (150 mL). The samples were freeze-dried 89 
for 24 h and a white powder was obtained. Lactide conversion ≥95% (1H-NMR). 1H-NMR 90 
[400 MHz, CDCl3, 25°C] PLA-C6H13: δH 5.10-5.28 (PLA-CHCH3COO-), 1.52-1.61 (PLA-91 
CHCH3COO-), 0.88-0.92 (-CH2CH3). PLA-C3F7, PLA-C6F13, PLA-C8F17, PLA-C11F23 and 92 
PLA-C13F27: δH 5.10-5.28 (PLA-CHCH3COO-), 4.50-4.70 (-OCH2CF2-), 1.52-1.61 (PLA-93 
CHCH3COO-). 
19F-NMR [400 MHz, CDCl3, 25°C] PLA-C3F7: δF -79.0 (-CF3), -118.7 (-94 
OCH2CF2-) and -125.7 (-CF2CF3); PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27: δF -95 
78.9 (-CF3), -117.7 (-OCH2CF2-), -120.0 (-(CF2)nCF2CF3), -120.7 (-OCH2CF2CF2CF2-), -121.4 96 
(-OCH2CF2CF2-) and -124.2 (-CF2CF3).  97 
2.3 Characterization 98 
All polymers were characterized by size exclusion chromatography (SEC) in chloroform at 30 99 
°C with a flow rate of 1 mL.min-1 by two columns (PL-gel 5µm MIXED-D 300 x 7.5 mm) 100 
calibrated against a curve based on poly(methyl methracrylate) standards (PMMA, Polymer 101 
Laboratories, Varian Inc.) The system was coupled to a refractive index detector 102 
(Spectrasystem RI-150, Thermo Electro Corp.). 1H and 19F-NMR spectra were obtained on a 103 
Bruker AVANCE III HD 400 MHz in CDCl3 at 25ºC.  104 
2.4 Interfacial surface tension  105 
 The interfacial surface tension was performed in a Tracker tensiometer (Teclis, 106 
France). PFH was previously filtrated by a column of aluminum oxide. A constant 2 µL PFH 107 
or sodium cholate drop was formed by a syringe and a G20 stainless steel needle inside an 108 
optical glass cuvette containing fixed polymer concentrations of 25 mg.mL-1 in chloroform or 109 
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dichloromethane previously filtered by 0.22 µm (Millipore). The temperature was kept at 20 110 
°C and the interfacial surface tension was determined from the drop profile employing the 111 
Laplace equation and the forces balance between capillarity and gravity.   112 
2.5 19F-NMR T1 and T2 Relaxation 113 
19F Spin-lattice and spin-spin relaxation measurements were performed at 25 ºC in CDCl3 or 114 
CD2Cl2 with fixed polymer concentrations of 25 mg.mL
-1. Samples containing 15 µL of PFH 115 
were also evaluated. The samples were not degassed. All experiments were performed on a 116 
Bruker AVANCE III HD NMR spectrometer operating at 9.4 T, equipped with a 5-mm 117 
multinuclear inverse detection probe, observing 19F and 1H nuclei at 376.49 and 400.13 MHz, 118 
respectively. 19F T1 was determined by the inversion-recovery pulse sequence (T1IR). The 119 
delay (τ) between the inversion and read-pulse was varied along 16 values (1 to 22 s). The 120 
total number of scans was 32, spectral width = 100 ppm and relaxation delay = 22 s. 19F T2 121 
values were measured by the PROJECT-CPMG pulse sequence along 15 values of τ (0.1 to 122 
2 ms) 30. The number of scans was 128, spectral width = 100 ppm and relaxation delay = 10 123 
s. Relaxation times were obtained by nonlinear least-squares fitting of a mono- exponential 124 
function with r2≥0.998 for all samples.  125 
 126 
2.6 Microcapsules Formulation 127 
Microcapsules were prepared by the emulsion-evaporation technique, as previously 128 
described 13, with minor modifications. Briefly, the desired amount of polymer was dissolved 129 
into 2 mL of chloroform or dichloromethane in a 50 mL glass flask. Afterwards, 50 µL of nile 130 
red (55 µg.mL-1) was added and the flask was sealed with a rubber cap. Next, 30 µL of PFH 131 
was introduced through the septum with constant stirring and the media was emulsified with 132 
10 mL of sodium cholate 1.5% (w/w) at 4 °C. The mixture was submitted to high-speed 133 
homogenization at 8.000 RPM using an Ultra-Turrax T25 (IKA) coupled with an SN25-10G 134 
dispersing tool in an ice bath for 1 minute. The solvent was removed by rotary evaporation 135 
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(Büchi) with a 30 °C water bath and recirculation chiller at -10 °C. A vacuum gradient from 136 
400 to 30 mbar in 7 steps of 5 minutes was employed. Afterwards, the total volume of each 137 
sample was completed to 10 mL with ultrapure water.  138 
2.7 Confocal Microscopy 139 
Microcapsules were washed twice with ultrapure water by centrifugation and resuspended in 140 
glycerol to minimize motion. All samples were observed in a Leica TCS SP5 confocal 141 
scanning microscope (Leica) with a 1 mW helium neon laser operating at excitation of 551 142 
nm and 636 nm of emission, Plan Achromat 63X objective (NA 1.40 oil immersion) and 143 
pinhole diameter at 71 nm. For diameter analysis, the measurements were performed in the 144 
equatorial plane of each capsule as previously described 13.  145 
2.8 Scanning Electron Microscopy 146 
Scanning electron microscopy was performed in a Merlin 6040 (Carl Zeiss, Germany) 147 
operating at 3 kV. All microcapsules were washed twice with ultrapure water by 148 
centrifugation to remove the excess of sodium cholate, deposited on carbon conductive 149 
double-sided tape (Euro-medex, France) and dried at room temperature. Afterwards, they 150 
were coated with a palladium–platinum layer of about 3 nm using a Cressington sputter-151 
coater 208HR with a rotary-planetary-tilt stage, fitted with an MTM-20 thickness controller. 152 
2.9 PFH encapsulation efficiency by 19F-NMR spectroscopy 153 
For PFH quantification, 1 mL of microcapsules was freeze-dried during 24 h employing an 154 
Alpha-1-2 LD apparatus (Christ). The flasks were hermetically sealed with a rubber cap and 155 
stored at -20 °C until analysis. The PFH encapsulation efficiency was determined as 156 
described by Diou et al. 29. A total volume of 1 mL of chloroform was introduced into the 157 
sealed tube by a needle, the suspension was vortexed (5 cycles of 30 seconds) and 158 
centrifuged at 0 °C for 10 minutes at 5000 rpm (Jouan CR4I centrifuge, Thermo Electron 159 
Corporation). The organic solution was collected in a cold room at 4 °C and introduced into 160 
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an NMR tube that was afterwards loaded with a stem coaxial insert containing TFA in D2O 161 
(12 µmol.mL-1) as external standard 31. All spectra were obtained at 4 °C on a Bruker Avance 162 
300 (400 MHz) spectrometer. The total amount of encapsulated PFH was determined based 163 
on a PFH calibration curve. For each MC sample, the integration of the TFA peak at -76.5 164 
ppm was determined as 3 and the resulting integration of the PFH CF3 at -81.2 ppm was 165 
used to calculate the PFH concentration in the NMR tube based to the equation of the 166 
calibration curve. 167 
2.10 Statistical analysis 168 
The statistical analysis was performed using Statistica™ 8.0 software (StatSoft Inc., Tulsa, 169 
USA). The data was analyzed by two-sided Student’s t-test and a statistical significance was 170 
set at the level of p<0.05. 171 
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3. Results and Discussion 172 
3.1 Polymers synthesis and characterization  173 
Six end-group fluorinated or alkylated polymers were synthesized by ring opening 174 
polymerization of D,L-lactide with appropriate initiator (hexanol or fluorinated alcohols) as 175 
previously described 14,19,28,32 (reaction yield > 85%). The polylactide main chain is 176 
constituted by ~140 repetitive units containing different lengths of end fluorinated-groups: 177 
polymers are designated according to the terminal group chemistry and length of fluorinated 178 
units as PLA-C6H13, PLA-C3F7, PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27. They 179 
were characterized by 1H and 19F-NMR and exhibited a molecular weight around 18000-180 
21000 g.mol-1 as assessed by NMR, with a narrow dispersity (Supporting information Figure 181 
S1 and Table S1).  182 
3.2 Polymers dynamics 183 
To explore the role and extent of fluorous interactions between the different PLA-CxF2x+1 and 184 
PFH during the formation of microcapsules, we have investigated interfacial properties, 185 
dynamics in solution as well as morphological features generated by each of these polymers. 186 
As fluorine recognition and compartmentalization are strictly dependent on the solvent’s 187 
character, the behavior and impact of polymer end-group chemistry was studied in two 188 
distinct solvents usually employed in the formulation of MC, namely, chloroform and 189 
dichloromethane25,26.  190 
The interfacial activity of the polymers was determined at the solvent/PFH and 191 
solvent/sodium cholate (SC) interfaces by interfacial surface tension measurements (Table 192 
1). At the solvent/SC interface, interfacial tension values were between 7–8 mN.m-1 in CHCl3 193 
or CH2Cl2, for all polymers, suggesting no specific solvent or end-group contribution to the 194 
interfacial activity. At the PFH/solvent interface, polymers dissolved in CHCl3 exhibited an 195 
interfacial tension average value of 3.0±0.05 mN.m-1 whereas 6.0±0.1 mN.m-1 was measured 196 
for polymers dissolved in CH2Cl2, indicating that CHCl3 favors PFH spreading. Nonetheless, 197 
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none of the polymers was able to decrease the interfacial tension compared to the solvent 198 
itself regardless the end-group chemistry or the length of the fluorinated end-group.  199 
Table 1. Interfacial tensions at the perfluorohexane/solvent and alkylated or fluorinated 200 
polymer/sodium cholate 1.5% (w/v) interfaces. All polymers were dissolved at 25 mg.mL-1 in 201 
chloroform or dichloromethane. All results are expressed in mN.m-1. 202 
 Chloroform Dichloromethane 
 PFH/solvent  Solvent/SC 1.5%  PFH/solvent  Solvent/SC 1.5%  
Solvent 3.2±0.3 7.5±0.3 6.0±0.3 8.1±0.2 
PLA-C6H13 3.0±0.5 7.5±0.2 6.2±0.5 8.0±0.2 
PLA-C3F7 3.0±0.3 7.0±0.1 6.1±0.7 7.5±0.3 
PLA-C6F13 3.0±0.5 7.1±0.5 6.2±0.4 7.7±0.5 
PLA-C8F17 3.1±0.4 7.1±0.2 5.9±0.4 7.7±0.4 
PLA-C11F23 3.0±0.3 7.2±0.3 5.9±0.3 7.8±0.2 
PLA-C13F27 3.1±0.4 7.4±0.1 6.1±0.4 7.6±0.1 
PFH-SC (1.5% w/v) interfacial tension was 22.5±0.2 mN.m
-1 203 
The lack of adsorption at the PFH/solvent interface might be explained by the mass ratio 204 
difference between the relatively small fluorinated blocks compared to the PLA main chain 205 
(C3 to C13 for fluorinated block vs. 140 repetitive units for PLA) and the conformation 206 
assumed by the polymer in solution. Indeed, as the PLA polymers are well solvated in CHCl3 207 
and CH2Cl2 (Hildebrand solubility parameter (  ) of 20.8 MPa
0.5 for unmodified PLA, 18.7 208 
MPa0.5 for CHCl3 and 20.2 MPa
0.5 for CH2Cl2 
33), a conformational rearrangement based on 209 
the higher solubility of the polymeric chains within the solvents may hide the fluorinated 210 
groups inside the PLA coil, hindering an effective interaction with the PFH phase 19.  211 
Although no interfacial activity was observed at the PFH/solvent interface during static 212 
measurements, the solvent-evaporation process is dynamic and associated with transitory 213 
interfacial instabilities due to system disorganization 34. Such constant rearrangement of 214 
water and organic solvent molecules may promote the formation of fluorinated domains 215 
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favorable for PFH encapsulation 35. Indeed, many studies carried on mixed systems, 216 
containing both fluorocarbons and organic solvents, showed the tendency of perfluoralkyl 217 
moieties to self-associate and generate fluorous compartments. This aggregation in rich 218 
fluorous domains is generally associated to a reduced mobility of fluorinated groups 26,36,37.  219 
To assess the behavior of the fluorinated chains in a more dynamic media containing PFH – 220 
a situation similar to what happens prior to solvent evaporation – the end-group mobility of 221 
three fluorinated polymers, PLA-C3F7, PLA-C8F17 and PLA-C13F27, was analyzed by fluorine 222 
NMR spectroscopy employing spin-lattice (T1) and spin-spin (T2) relaxation measurements at 223 
fixed polymer concentration of 25 mg.mL-1 and 15 µL of PFH (corresponding to the 224 
formulation conditions). Accordingly, the CF3 group dynamics in each solvent was probed in 225 
presence and absence of PFH in the solvent. Unfortunately, some of the PFH resonances 226 
overlapped with the CF3 polymer signals for PLA-C8F17 and PLA-C13F27 in both solvents. Only 227 
PLA-C3F7 exhibited well segregated resonance from those of PFH because of the different 228 
chemical environments, which permitted a resonance shift towards lower magnetic fields, not 229 
overlapping with PFH as displayed in Figure 1. The nomenclature and 19F-NMR peak 230 
labeling consists alphabetically with the position of the fluorinated resonance respective to 231 
the PLA chain  38,39.  232 
  233 
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 234 
Figure 1. Magnified CF3 and CF2 regions of the 
19F-NMR spectra for PLA-C3F7, PLA-C8F17 235 
and PLA-C13F27 in CDCl3. The insets (left) exhibit the CF3 resonance in a mixed system of 236 
polymer and perfluorohexane. 19F peak assignment is indicated in the top of each image.  237 
T2 analysis revealed that the CF3 resonance mobility decreased strongly for polymers 238 
functionalized with longer fluorinated units in the order C3F7>C8F17>C13F27 for both solvents 239 
(Table 2). Such reduction in the local fluorine dynamics according to chain length is related 240 
to the strong electronegativity of the C-F bond that generates linear and rigid chain 241 
conformations, reducing the segmental mobility as the chain length increases 40. 242 
Nonetheless, samples dissolved in CDCl3 showed smaller relaxation values compared to 243 
their counterparts prepared in CD2Cl2: this effect is clearly illustrated by the CF3 resonance of 244 
PLA-C3F7, with T2 of 540±50 ms in CDCl3 and 1530±150 ms in CD2Cl2. Such results were also 245 
confirmed by T1 measurements (Supporting information Table S2). These significant 246 
changes in relaxation times indicate that chloroform is not a good solvent for the fluorinated 247 
end-groups and drives self-association of 19F containing units.  248 
  249 
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Table 2. 19F spin-spin relaxation (T2) values of CF3 resonances for samples dissolved in 250 
deuterated chloroform or dichloromethane in presence of absence of perfluorohexane. All 251 
polymers were dissolved at fixed concentration of 25 mg.mL-1 (Experiment performed in 252 
duplicate, n=2).  253 
Sample T2 (ms) T2 (ms) 
CDCl3 CDCl3+PFH CD2Cl2 CD2Cl2+PFH 
PLA-C3F7 540±50 81±15 1530±150 1710±250 
PLA-C8F17 210±20 --- 1263±165 --- 
PLA-C13F27 76±10 --- 790±50 --- 
 254 
Afterwards, PFH was added to each polymer solution to simulate the system behavior just 255 
before emulsification with sodium cholate. In CD2Cl2, T2 varied from 1530±150 ms to 256 
1710±250 ms in presence of PFH, showing that the end-group dynamics is not significantly 257 
affected by PFH addition in the media (p = 0.475). However, in CDCl3, the CF3 signal of PLA-258 
C3F7 showed a significant T2 decrease with PFH, from 540±50 ms to 81±15 ms (p <0.05). 259 
This lower mobility denotes a polymer rearrangement in presence of PFH evidencing an 260 
increased tendency for the fluorinated segments to associate with each other (Figure 2). 261 
Indeed, in CHCl3, addition of PFH further decreases the solubility of the fluorinated segments 262 
which promotes dipolar interactions between the fluorinated end-group and PFH. These 263 
more efficient interactions in CHCl3 suggest formation of F-rich domains where the reduced 264 
mobility of the fluorinated segment leads to shorter T2 values.  265 
 266 
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 267 
Figure 2. T2 decay profiles for the CF3 resonance of PLA-C3F7 in CDCl3 (A) and CD2Cl2 (B) 268 
without (open circles) and with perfluorohexane (dark circles).  269 
According to those results, the introduction of PFH was able to reduce the local end-270 
fluorinated group mobility of PLA-C3F7 in CDCl3. As PFH is well dissolved in chloroform, its 271 
contact with the fluorinated units may lead to the formation of fluorophilic domains, a process 272 
that might also depends on the length of the fluorinated group. This scenario, however, 273 
illustrates the system’s behavior only in stable organic solutions; during the solvent-274 
evaporation process in which MCs are formulated, transitory and thermodynamically 275 
unstable interfaces are created. Therefore, the ability of each fluorinated derivative to better 276 
stabilize and retain PFH as a liquid core was further studied in MCs formulations.    277 
3.2 Solvent Influence on MC formulation  278 
The impact of the fluorinated end-groups on the final morphology of microcapsules was then 279 
studied for all synthesized polymers. All microcapsules were initially formulated with fixed 280 
amounts of polymer (50 mg) that were dissolved either in chloroform or dichloromethane and 281 
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subsequently submitted to the same solvent-evaporation process. The encapsulation 282 
efficiency (EE) of PFH was quantified in freeze-dried samples by 19F-NMR and the size of all 283 
MCs was measured by confocal microscopy as listed in Table 3. 284 
Table 3. Encapsulation efficiency and size of microcapsules formulated with 50 mg of 285 
polymer prepared in chloroform and dichloromethane. 286 
Sample Chloroform Dichloromethane 
 Size (µm)* PFH EE (%) Size (µm)* PFH EE (%) 
PLA-C6H13 4.2±1.0 5.5±0.2 4.8±0.8 12.3±0.2 
PLA-C3F7 4.4±0.6 10.1±0.2 4.7±0.8 9.1±0.1 
PLA-C6F13 4.8±1.0 12.7±0.2 4.6±1.0 13.1±1.3 
PLA-C8F17 4.6±0.8 10.3±0.5 4.9±1.2 11.1±0.2 
PLA-C11F23 5.2±1.4 11.1±1.4 4.8±0.9 7.1±0.1 
PLA-C13F27 5.2±1.0 11.4±1.5 5.3±0.6 10.0±0.7 
*All measurements correspond to observation and analysis of at least 100 microcapsules per each group. 287 
As determined by 19F NMR, the non-fluorinated polymer, PLA-C6H13, presented an 288 
encapsulation efficiency of 5.5±0.1% when prepared in CHCl3. The use of fluorinated 289 
polymers led to a 2-fold increase in PFH encapsulation efficiency, reaching 11±3.0% without 290 
any significant distinction as a function of the fluorinated end-group length (Table 3). The 291 
reduced end-group mobility of fluorinated polymers in CDCl3 containing PFH was translated 292 
into higher encapsulation efficiencies. Altogether, these results evidence the ability of 293 
fluorinated polymers to interact with the fluorocarbon phase and enhance its stabilization 294 
inside the organic phase, as previously reported for nanocapsules 14. For microcapsules 295 
prepared in CH2Cl2, no trend was observed for the encapsulation efficiency, probably due the 296 
absence of specific interactions between PFH and the polymer (Table 2).  297 
Nonetheless, PLA or PLGA polymers are able to encapsulate higher amounts of PFH into 298 
MCs (~40%) 13, the discrepancy with our results may be related to the fast process of solvent 299 
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evaporation employed here, whereas Mousnier et al. have evaporated the organic solvent 300 
slowly at ambient pressure13.   301 
 Although all samples were predominately smooth as shown by SEM in Figures 3 and 302 
4 (bottom), a certain amount of rough shelled MCs were also observed in all images. 303 
According to Chung, et al., this morphological variation might be related to the fast 304 
evaporation process used, which promoted an uneven polymer concentration gradient 305 
towards the interface 41. Also, a partial PFH vaporization during the solvent evaporation step 306 
(performed at 30 °C) may have caused a volumetric expansion of the MCs and, as the 307 
temperature dropped, a subsequent shrinkage altered the continuous spreading of the 308 
polymer at the interface as previously reported by Lebeveda et al. for PFH containing 309 
microspheres 42. 310 
 311 
Figure 3. Confocal (top) and scanning electron microscopy (bottom) images of 312 
microcapsules produced in chloroform. Scale bar represents 10 µm. 313 
 314 
Figure 4. Confocal (top) and scanning electron microscopy (bottom) images of 315 
microcapsules produced in dichloromethane. Scale bar represents 10 µm. 316 
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A clear and subtle distinction on MC morphology was observed according to the fluorinated 317 
end-group length in both solvents. In all cases, PLA-C6H13, PLA-C3F7 and PLA-C6F13 318 
exhibited core-shell morphologies comprising a well-centered PFH phase; however, as the 319 
end-group length increased to C8F17, C11F23 and C13F27 higher extents of randomly distributed 320 
PFH cores were observed as displayed by the white arrows in Figures 3 and 4 (top). In 321 
CH2Cl2, MCs still possess a distinctive core shell structure but the inner PFH core is 322 
displaced from the center of the MC. Such decentered morphology had already been 323 
observed 13. Formulation in CHCl3 leads to a mixture of structure with well centered MC and 324 
with MC having multi-cores of PFH.  325 
Regardless of the solvent employed, samples prepared with short fluorinated or non-326 
fluorinated end-groups, PLA-C3F7 and PLA-C6F13 or PLA-C6H13, presented the formation of 327 
core-shell capsules. Only MCs formulated with longer fluorinated groups, PLA-C8F17, PLA-328 
C11F23 and PLA-C13F27, led to the appearance of different morphologies, either in chloroform 329 
or dichloromethane, indicating that the shell precipitates prior to complete PFH nucleation at 330 
the center of the organic droplet. Thus, the length of the fluorinated end-group played an 331 
important role in the fluorocarbon nucleation process, suggesting that longer fluorous chains 332 
were able to better interact and restrain the PFH diffusion as illustrated in Figure 5. 333 
  334 
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 335 
 336 
Figure 5. Schematic representation of the perfluorohexane phase-separation and nucleation 337 
process in the organic phase containing fluorinated polymers of distinct end-group lengths. 338 
The different morphologies generated in each solvent are possibly related with the extent of 339 
fluorous interactions, PFH miscibility as well as solvent evaporation rate. In dichloromethane, 340 
the formation of decentered capsules for the longer F-units samples, such as PLA-C13F27, 341 
probably reflected the reduced extent of interactions between the end-groups and PFH. 342 
Nonetheless, such samples were still able to alter the nucleation pattern, inducing the PFH to 343 
accumulate towards the drop’s periphery, also suggesting the fluorinated segregation effect. 344 
The obtained decentered morphologies are, however, favored by the solvent’s lower boiling 345 
point (39.6 °C for CH2Cl2 vs. 61.2 °C for CHCl3) that accelerates the onset of polymer 346 
precipitation. 347 
In chloroform, the shell of polymers with longer fluorinated groups precipitates before the 348 
complete fluorocarbon nucleation restraining PFH diffusion and causes multiple PFH cores 349 
dispersed inside the rigid polymeric phase. As disclosed by T2 results, the PFH is able to 350 
interact more efficiently with the fluorinated end-groups in this solvent. Thus, such structure 351 
21 
 
is probably attributable to formation of F-rich domains driven by the end-group polymer 352 
arrangement to minimize contact with the surrounding polymer. This effect indicates that 353 
longer fluorinated units interact more importantly with PFH.  354 
3.3 Influence of polymer concentration on MC morphology  355 
To further evaluate the end-group chemistry and length influence on microcapsules structure, 356 
samples PLA-C6H13, PLA-C3F7, PLA-C8F17 and PLA-C13F27 were prepared only in chloroform 357 
using different polymer masses (12.5, 25, 50 and 100 mg) and constant PFH volume of 30 358 
µL.  359 
Samples prepared with 12.5 mg presented core-shell structures with thin and smooth 360 
polymer layers that were predominant for all polymers, independently of end-group chemistry 361 
or length as shown in Figure 6. The increase of polymer mass to 25 mg altered only the 362 
morphology of MCs having the longest fluorinated group: PLA-C13F27 by formation of 363 
multinucleated capsules (42±10%) as displayed by the white arrow in Figure 6. The 364 
percentage of multiple PFH cores for PLA-C13F27 became more obvious for 50 and 100 mg, 365 
in which the total amount of multinucleated MCs increased from 60±5% to 91±3%, 366 
respectively. The same effect but at a lower extent was observed for PLA-C8F17, as thin-367 
shelled MCs are observed in the formulations containing 25 mg and multinucleated 368 
morphologies increased from 10±2% to 56±7% for 50 and 100 mg, respectively. A similar 369 
behavior was observed for MC formulated with the polymer containing the shortest fluorine 370 
end-group, PLA-C3F7, as core-shell structures predominated until a polymer mass of 100 mg, 371 
in which a total of 45±5% of multinucleated MC were found. In contrast, MC formulated with 372 
the non-fluorinated sample, PLA-C6H13, exhibited core-shell morphologies for all of the tested 373 
polymer masses.  374 
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 375 
Figure 6. Confocal microscopy images of microcapsules formulated in chloroform with non-376 
fluorinated (PLA-C6H13) and fluorinated (PLA-C3F7, PLA-C8F17 and PLA-C13F27) polymers with 377 
varied polymer masses: 100, 50, 25 and 12.5 mg. Scale bar of 10 µm. 378 
Despite heterogeneity of morphology within the same sample, a clear effect of the polymer 379 
end-group chemistry and fluorinated length was evidenced in the capsule’s morphology. 380 
Compared to PLA-C6H13, polymers containing F-groups generated MCs with decentered 381 
and/or multiple PFH cores. At high fluorinated polymer mass, the dominant morphology 382 
whatever the fluorinated length block consists in multinucleated capsules. This increase in 383 
polymer mass favored the formation of richer fluorophilic domains – in the order of 384 
C3F7<C8F17<C13F27 – that altered the polymeric phase dynamics, reducing the migration of 385 
PFH to the center of the organic drop.  386 
4. Conclusion 387 
We have successfully synthesized and characterized poly(lactide) end-group fluorinated 388 
polymers for improved fluorous interaction with PFH. The presence of fluorinated end-groups 389 
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provided more favorable interfaces with perfluorohexane in organic solution of chloroform 390 
with fluorinated end-group length dependency, as revealed by spin-spin relaxation 391 
measurements. The formation of fluorophilic environment is reflected with improved 392 
perfluorohexane encapsulation efficiencies into microcapsules and by modifying the final 393 
morphology, particularly in the case of longer fluorinated end-groups and important polymer 394 
masses. 395 
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